• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 3. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 4. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives N-phenylureas

1-(4-chlorophenyl)-3-(1,3-thiazol-2-yl)urea: A Comprehensive Overview

1-(4-Chlorophenyl)-3-(1,3-thiazol-2-yl)urea, with the CAS number 69123-55-3, is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This urea derivative is characterized by its unique structural features, which include a chlorophenyl group and a thiazole moiety. These functional groups contribute to its potential therapeutic applications and make it an intriguing subject for ongoing studies.

The chlorophenyl group is known for its ability to enhance the lipophilicity of molecules, which can improve their ability to cross biological membranes. This property is particularly valuable in drug design, as it can enhance the bioavailability and efficacy of potential therapeutic agents. The thiazole moiety, on the other hand, is a common heterocyclic ring found in many biologically active compounds. It often confers enhanced stability and specific binding properties to molecules, making it a valuable component in drug development.

1-(4-Chlorophenyl)-3-(1,3-thiazol-2-yl)urea has been extensively studied for its potential as an antifungal agent. Recent research has shown that this compound exhibits potent antifungal activity against a variety of pathogenic fungi, including Candida albicans and Aspergillus fumigatus. The mechanism of action is believed to involve disruption of fungal cell membranes and inhibition of essential enzymes involved in fungal metabolism. These findings have significant implications for the development of new antifungal therapies, particularly in the context of increasing resistance to existing antifungal drugs.

In addition to its antifungal properties, 1-(4-Chlorophenyl)-3-(1,3-thiazol-2-yl)urea has also shown promise as an anticancer agent. Studies have demonstrated that this compound can induce apoptosis in various cancer cell lines, including breast cancer and colon cancer cells. The mechanism behind this anticancer activity is thought to involve the modulation of key signaling pathways involved in cell proliferation and survival. These findings suggest that 1-(4-Chlorophenyl)-3-(1,3-thiazol-2-yl)urea could be a valuable lead compound for the development of novel anticancer drugs.

The synthesis of 1-(4-Chlorophenyl)-3-(1,3-thiazol-2-yl)urea has been well-documented in the literature. Typically, it involves the reaction of 4-chlorophenyl isocyanate with 2-aminothiazole in an appropriate solvent. This synthetic route is straightforward and can be easily scaled up for large-scale production. The purity and yield of the final product can be optimized by carefully controlling reaction conditions such as temperature, solvent choice, and reaction time.

To further explore the potential applications of 1-(4-Chlorophenyl)-3-(1,3-thiazol-2-yl)urea, several research groups have conducted detailed pharmacokinetic and pharmacodynamic studies. These studies have provided valuable insights into the absorption, distribution, metabolism, and excretion (ADME) properties of the compound. For instance, it has been found that 1-(4-Chlorophenyl)-3-(1,3-thiazol-2-yl)urea exhibits good oral bioavailability and a favorable pharmacokinetic profile, making it suitable for oral administration in therapeutic settings.

In preclinical studies, 1-(4-Chlorophenyl)-3-(1,3-thiazol-2-yl)urea has demonstrated low toxicity and high selectivity towards target cells. This favorable safety profile is crucial for its potential use as a therapeutic agent. However, further clinical trials are necessary to fully evaluate its safety and efficacy in human subjects. Ongoing research aims to optimize the formulation and dosing regimens to maximize therapeutic benefits while minimizing potential side effects.

The potential applications of 1-(4-Chlorophenyl)-3-(1,3-thiazol-2-yl)urea extend beyond antifungal and anticancer therapies. Recent studies have also explored its anti-inflammatory properties. Preliminary results suggest that this compound can inhibit pro-inflammatory cytokines such as TNF-alpha and IL-6, which are involved in various inflammatory diseases. This finding opens up new avenues for its use in treating conditions such as rheumatoid arthritis and inflammatory bowel disease.

In conclusion, 1-(4-Chlorophenyl)-3-(1,3-thiazol-2-yl)urea, with CAS number 69123-55-3, is a promising compound with diverse biological activities. Its unique structural features make it a valuable candidate for further development in various therapeutic areas. Ongoing research continues to uncover new insights into its mechanisms of action and potential applications, highlighting its significance in the field of medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)